Syed Rizvi, MD

home / authors / syed-rizvi-md

Articles

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

Syed Rizvi, MD
April 24th 2020

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Read More

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

Syed Rizvi, MD
April 16th 2020

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Read More

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

Syed Rizvi, MD
March 19th 2020

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Read More

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

Syed Rizvi, MD
February 11th 2020

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC